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Abstract: In the context of antibacterial drug discovery resurgence, novel therapeutic targets and new 
compounds with alternative mechanisms of action are of paramount importance. We focused on UDP-N-
acetylenolpyruvylglucosamine reductase (i.e. MurB), an underexploited target enzyme that is involved in early 
steps of bacterial peptidoglycan biosynthesis. On the basis of the recently reported crystal structure of MurB in 
complex with NADP+, a pharmacopohore model was generated and used in a virtual screening campaign with 
combined structure-based and ligand-based approaches. In order to explore chemical space around hit 
compounds, further similarity search and organic synthesis was employed to obtain several compounds with 
micromolar IC50 values on MurB. The best inhibitors in the reported series of 5-substituted tetrazol-2-yl 
acetamides were compounds 13, 26 and 30 with IC50 values of 34, 28 and 25 µM, respectively. None of the 
reported compounds possessed in vitro antimicrobial activity against S. aureus and E. coli. 
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Introduction 
Recently, resurgence in antibacterial drug discovery can be observed, especially in the context of emerging 
resistant bacteria.[1] Resistant and multi-drug resistant pathogens are reported globally in general community and 
hospitals, which makes novel antibacterial discovery an immediate and important endeavour.[2] A steady stream 
of innovative molecular scaffolds, revisits of the older data, unification of interdisciplinary drug-discovery 
approaches and utilisation of underexploited therapeutic targets are decisive approaches in our pursuit of novel 
drugs.[3-5] Among the most important and underutilised therapeutic targets in antibacterial drug discovery are 
early steps of bacterial cell wall biosynthesis.[6]  
Peptidoglycan is a key component of bacterial cell wall. It provides bacteria with the necessary structural 
integrity to withstand the osmotic pressure gradient between the cytoplasm and the cell exterior. It is composed 
of alternating disaccharide units of N-acetyl muramic acid (MurNAc) and N-acetyl glucosamine (GlcNAc) that 
are cross-linked with short peptide chains.[7] Peptidoglycan biosynthesis requires approximately 20 reactions, 
catalysed by different enzymes.[8] Each enzyme in this pathway is essential and unique for bacteria and thus 
important and selective target for the discovery of new antibacterial agents.[9,10]    
In this work, we have focused on the UDP-N-acetylenolpyruvylglucosamine reductase or MurB.[11] The enzyme 
reduces the enolpyruvyl moiety of UDP-N-acetyl glucosamine-enolpyruvate (UDP-GlcNAc-EP), produced by 
MurA (Figure 1). MurB contains one molecule of non-covalently bound flavin adenine dinucleotide (FAD) that, 
during the catalytic process, serves as a hydride transfer mediator between β-nicotinamide dinucleotide 
phosphate (NADPH) and the enolpyruvyl substrate. First, NADPH binds to the enzyme and transfers the 4-pro-
S hydrogen to N-5 atom of the enzyme-bound FAD, then NADP+ dissociates from the enzyme. In the second 
half-reaction, substrate UDP-GlcNAc-EP binds to MurB with the following hydride transfer from FADH2 to 
vinyl ether of the UDP substrate, forming UDP-N-acetyl muramic acid (UDP-MurNAc).[12] 
 
Figure 1: Catalytic consecutive and two-step mechanism of MurB. 
There are only few MurB inhibitors present in the literature and compounds 1 and 2 (Figure 2) were among the 
first reported. Imidazolinone 2 is a result of optimisation campaign where the heterocycle core replaced the 
starting 4-thiazolidinone moiety. Both heterocycles were designed to mimic the diphosphate moiety of UDP-
GlcNAc-EP substrate.[13, 14] Compound 3 (Figure 2) was identified by high-throughput (HTS) screening as MurB 
inhibitor with low micromolar Kd value. [15] Furthermore, alkyl pyrazolidinedione derivatives were found as 
good inhibitors of S. aureus and E. coli MurB (e.g. 4, Figure 2).[16, 17] A series of phenyl thiazolyl urea (e.g. 5, 
Figure 2) and carbamate analogues inhibited the enzyme in the low micromolar range.[18] Most published MurB 
inhibitors possessed promising antibacterial activities, however, when tested in the presence of 4% bovine 
serum albumin, their activities were lost, indicating high-protein binding properties of compounds. No novel 
inhibitors of MurB have been reported in the last decade, while the compounds described above were not 
pursued further due to their unfavourable physico-chemical properties. Therefore we sought to identify novel 
compounds with improved physico-chemical properties and greater optimisation potential. Overall, MurB is an 
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attractive target in antibacterial drug discovery and herein we here report a successful pharmacophore-based in-
silico study that led to the discovery of novel structural class of MurB inhibitors. 
 
Figure 2: Previously described MurB inhibitors present in the scientific literature. 
Methods and Materials 
Pharmacophore preparation and Virtual Screening: Protocol consisted of pharmacophore modelling, 
compound collection from ZINC version 12, database preparation and virtual screening.[19] Pharmacophore 
models can be described as representation or 3D-arrangement of the chemical features and steric limitations, 
postulated as necessary for a small molecule to interact with its target.[20] These features are presented in Figure 
3 and Figure 4. MurB with non-covalently bound FAD and active site defined as space occupied by NADP 
(PDB IDs: 4JAY, 4JB1) was used in an automatic generation of three-dimensional structure-based 
pharmacophore using an effective LigandScout (Software-Entwicklungs und Consulting GmbH, Maria 
Enzersdorf, Austria) software package. Ten or less pharmacophoric features were used for pharmacophore 
generation with additional generation of exclusion volume spheres on the basis of available space at the active 
site. Resulting models are depicted in Figure 3.[21] 
   
Figure 3: Left: pharmacophore, created on the basis of NADP, chain A (PDB ID: 4JAY) with superposed 
shared pharmacophore with UDP-GlcNAc-EP (PDB ID: 2MBR). Middle: pharmacophore, created with 
superposed NADP. Right: pharmacophore, created with added exclusion sphere coat representing the available 
space in the active site (yellow – planar/aromatic with tolerance sphere of 1.5 Å, red – H-bond acceptor with 
vector and tolerance sphere of 1.5 Å, green – H-bond donor with vector and tolerance sphere of 1.5 Å, centered 
red sphere – ionisable feature with tolerance of 2.15 Å, grey – exclusion spheres with tolerance of 1 Å). 
The created pharmacophore was validated with the superposition and analysis of MurB in complex with UDP-
GlcNAc-EP.[22] Upon structural analysis, NADP (PDB ID: 4JB1; Figure 4) presents the nicotinamide terminal 
moiety in the close proximity to the FAD flavin mononuleotide N-5 atom and Glu335 and Ser239 residues, 
consecutively enabling the transfer of hydride for the reduction of FAD. Similar positioning can be observed for 
the substrate UDP-GlcNAc-EP (PDB ID: 2MBR) where the terminal carboxyvinyl moiety occupies the same 
space and the alkene fragment is positioned in close proximity to the N-5 atom of FAD(H2) and Glu325 and 
Ser229 residues, for final substrate reduction towards UDP-MurNAc and NADP. Other terminus of both 
substrates diverged positionally and uridine diphosphate or adenine diphosphate nucleotides were observed at 
distinct binding modes for UDP-GlcNAc-EP and NADP, respectively. Using LigandScout software, a three 
dimensional pharmacophore for UDP-GlcNAc-EP in the active site was created, aligned to preceding 
pharmacophore model based on nicotinamide dinucleotide phosphate and a shared pharmacophore created, i.e. 
pharmacophore where individual pharmacophoric elements are shared by multiple structures. The produced 
final shared 3D pharmacophore model was superimposed on the starting pharmacophore model and was found 
to be nearly identical apart from terminal H-bond donor/acceptor motif typical of terminal carboxamide (Figure 
1, left).[23] The final production pharmacophore model based on the MurB in complex with NADP+ (PDB ID 
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4JAY) was thus refined by removing features, adjusting the tolerance sphere size and definition of exclusion 
spheres around the nicotinamide adenine dinucleotide phosphate (Figure 4). 
  
Figure 4: Left: superposition of UDP-GlcNAc-EP (blue, PDB ID: 2MBR) and NADP (cyan with coloured atom 
types, PDB ID: 4JAY); FAD can be observed in almost identical binding mode. Right: calculated 
pharmacophore: hydrophobic 46.571907, -5.837457, 11.458156; ionisable 45.4222 -11.2288 11.2484; ionisable 
45.8758 -13.7696 11.946; HBA 52.896 -10.663 12.334, 50.177 -10.402 13.677; HBA 53.257 -9.782 15.791, 
50.177 -10.402 13.677; HBA 47.614 -13.199 7.989, 47.208 -13.871 11.119; HBA 43.817, -13.738, 7.969, 
45.229 -11.925 9.78; HBA 47.614 -13.199 7.989, 45.229 -11.925 9.78; HBA 43.132 -3.175 13.229, 45.933 -
2.903 13.325; HBD 47.234 -3.916 14.773; 46.564 -1.598 16.459. 
Compounds were collected from ZINC 12 as Drugs Now subset (11 538 905 compounds) and database for the 
virtual screening protocol was prepared with consecutive filtering steps. First, the database was checked for 
PAINS (pan-assay interference compounds) and known and predicted aggregators were filtered out using 
FILTER software from OpenEye (OpenEye Scientific Software, Inc., Santa Fe, NM, USA; 
www.eyesopen.com). [24,25] Database was further pruned to eliminate structural faults, metals (metal complexes) 
and reactive functional groups that would pose frequent-hitter and high reactivity problems.[26] Molecules with 
molecular mass between 250-800 Da were retained to obtain a final collection of 4 755 936 compounds. Three-
dimensional conformer database was prepared with OpenEye (OpenEye Scientific Software, Inc., Santa Fe, 
NM, USA; www.eyesopen.com) OMEGA2 omega-fast protocol. Maximum number of conformations was set at 
25, rms threshold of 0.8 was used and energy window of 10 with 4000 max pool size with ring and nitrogen 
enumeration, molecules were used as reported in ZINC database without calculating all possible tautomer 
structures and ionizations.[27] Final LigandScout ldb database was created using Idbgen software from 
Inte:Ligand (Software-Entwicklungs und Consulting GmbH, Maria Enzersdorf, Austria) (Figure 5). 
 
Figure 5: Preparation of ZINC database for virtual screening step using LigandScout. 
Virtual screening was performed using Inte:Ligand LigandScout software with Pharmacophore-Fit scoring 
function. Exclusion spheres were considered in the calculation with minimum of three required pharmacophoric 
features. Top ranked and commercially available compounds were purchased (Table 1) and biologically 
evaluated as described below. Amongst 12 purchased and biologically evaluated compounds a hit compound 13 
was identified, and IC50 value was determined to be 34 µM on MurB.  
 
Molecular docking: Compounds were evaluated by FILTER 2.5.1.4 software (OpenEye Scientific Software, 
Inc., Santa Fe, NM, USA; www.eyesopen.com) for possible aggregation properties. 3D conformer library was 
generated with OMEGA2 2.5.1.4 software from OpenEye with 3000 maximum conformations per compound, 
rms of 0.5 and considered all possible stereoisomers of compounds.[27] Receptor was prepared from X-ray 
crystal structure of MurB in complex with NADP+ (PDB ID: 4JAY) active site, chain A with Make Receptor 
3.2.0.2 software from OpenEye (OpenEye Scientific Software, Inc., Santa Fe, NM, USA; www.eyesopen.com) 
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with FAD molecule in-place. Box with the volume of 7791 Å3 (17.00 × 25.00 × 18.33 Å) around NADP+ ligand 
was defined and balanced shape potential calculated. Pocket volume was 1403 Å3 and no constraints were used 
in docking runs. First, NAP co-crystalized substrate was extracted from the receptor and re-docking experiment 
was performed for validation of experiment. 3D conformer library for the NAP substrate (PDB ID: 4JAY) was 
prepared using Omega2 from OpenEye (3000 conformations, RMS 0.5, flipper true parameters) and the 
substrate was re-docked with HYBRID 3.2.0.2 from OpenEye OEDocking module with high resolution docking 
parameter enabled. Reproduction of experimentally determined binding mode (PDB ID: 4JAY) with an RMSD 
of 0.605 Å was successful. Then, an enrichment study was performed using a 3D conformer library of reported 
tetrazoles and a libraray of 1000 decoy molecules prepared by Schrödinger (Omega2 from OpenEye, validation 
experiment parameters).[28] Both libraries were docked for further binding mode studies and all active 
compounds (25, 18, 22, 30, 26 and 13) were ranked at the top 6 % of the entire decoy-test library. 
 
Analogue identification: With the OpenBabel software, a path-based fingerprint FP2 which indexes linear 
fragments of up to 7 atoms (similar to the Daylight fingerprints) was calculated for the main ZINC compound 
vendor catalogues (namely Enamine, ChemBridge, Vitas-M and Princeton Biomolecular Research) and fast 
search index created for the compound databases . Finally the created databases were searched for compounds 
with similar chemical space to the query compound 13.[29]  
 
Cloning, overproduction and purification of MurB from E. coli: The E. coli murB gene was amplified from 
a DH5α strain (Invitrogen) using the primers 5’- GCGTGAATTCATGAACCACTCCTTAAAACCC-3’ and 5’- 
CTACAAGCTTTCATGAAATTGTCTCCACTGCGC -3’. The primer upstream of the start codon (underlined) 
contained an engineered EcoRI site (in bold). The primer 3’ to the gene contained an engineered HindIII site (in 
bold). The amplified product was digested by EcoRI and HindIII and inserted between the compatible EcoRI 
and HindIII sites in vector pET2130 (T7 promoter), generating a plasmid that encodes MurB with a His6 N-
terminal extension. The construction was verified by DNA sequencing (Eurofins-MWG). Plasmid 
pET2130::murBEc was transformed into E. coli BL21(DE3) (Novagen) for expression experiments.[30] 
 
An overnight preculture of E. coli BL21(DE3) harbouring pET2130::murB was used to inoculate 1 liter of 2YT 
supplemented with 100 μg mL-1 ampicillin. The culture was incubated at 37°C with shaking until the optical 
density at 600 nm reached 0.8. Isopropyl ß-D-thiogalactopyranoside was added at a final concentration of 1 mM, 
and incubation was continued for 3 h at 37°C with shaking. The cells were harvested at 4°C, and the pellet was 
washed with cold 20 mM phosphate buffer, pH 7.2, containing 1 mM dithiothreitol (buffer A). Bacteria were 
resuspended in buffer A (10 mL) and disrupted by sonication in the cold. The resulting suspension was 
centrifuged at 4°C for 30 min at 200,000 g and the pellet was discarded. The supernatant was kept at -20°C. 
The His6-tagged MurB protein was purified on Ni2+-nitrilotriacetate-agarose following the manufacturer’s 
recommendations (Qiagen). All procedures were performed at 4°C. The supernatant was mixed for 1 h with the 
polymer, which had previously been washed with buffer A containing 0.3 M KCl and 10 mM imidazole. The 
washing and elution steps were performed with a discontinuous gradient of imidazole (20-300 mM) in buffer A 
containing 0.3 M KCl. Protein contents were analyzed by sodium dodecyl sulfate-polyacrylamide gel 
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electrophoresis. Relevant fractions were pooled and dialyzed against buffer A. Glycerol (10% final 
concentration) was added for storage of the protein at -20°C.  
 
MurB inhibition assay: The inhibition of MurB enzyme was measured with a continuous assay by monitoring 
the oxidation of NADPH.[30] The reaction mixture with final volume of 200 µL contained 50 mM Tris-HCl (pH 
8.0), 10 mM KCl, 100 µM NADPH, 50 µM UDP-GlcNAc-EP, and 100 µM of compound dissolved in DMSO. 
All of the compounds were soluble in the final assay mixture containing 2% of DMSO (v/v). The reaction was 
initiated by the addition of enzyme. The decrease in absorbance at 340 nm was monitored over 10 min at 37 °C. 
The residual activity was calculated with respect to a similar assay without the inhibitors. All the experiments 
were performed in triplicates. The IC50 values were determined at seven different concentrations of inhibitor and 
were calculated from the fitted regression equations using the logit-log plot.  
For the most active compound 30, Ki determinations were performed under similar assay conditions as 
described above. First, the concentrations of NADPH (25, 50, 75, 100 and 200 µM) were varied at fixed 
concentration of UDP-GlcNAc-EP (50 µM). Then the concentrations of UDP-GlcNAc-EP (25, 50, 75 and 100 
µM) were varied at fixed concentration of NADPH (100 µM). The concentrations of compounds 30 were 0, 10, 
20, 30, 50, 75 and 100 µM. All experiments were performed in triplicates. The resulting data was analysed using 
the SigmaPlot 12 software and fitted to competitive, uncompetitive, non-competitive and mixed type inhibition 
models. The mode of inhibition and Ki values were chosen from the best ranking model, as calculated by the 
software. A representative graph depicting the best fit model for compound 30 is shown in Figure 6. 
Figure 6: Lineweaver-Burk diagram of non-competitive binding mode of compound 30 versus NADPH. The 
concentrations of NADPH (25, 50, 75, 100 and 200 µM) were varied at fixed concentration of UDP-GlcNAc-EP 
(50 µM). The concentrations of inhibitor were 0, 10, 20, 30, 50, 75 and 100 µM. 
 
Microbiological evaluation: The antimicrobial activities for compounds were determined by broth 
microdilution in Luria Broth Miller (LB) against S. aureus (ATCC 29213) and E. coli (ATCC 25922). All of the 
experminents were performed according to CLSI guidelines and European Committee for Antimicrobial 
Susceptibility Testing recommendations.[31] Bacterial suspension of specific bacterial strain equivalent to 0.5 
MacFarland turbidity standard (approximately 1 × 108 CFU/mL) was diluted with LB broth to obtain a final 
inocolum of 5 × 105 CFU/mL in the assay. The compounds were dissolved in DMSO and then diluted 40-fold in 
LB, just before use. Bacterial suspension and test compound solution were mixed together in the 96-well plate 
(final volume, 200 µL) and incubated for 18-24 h at 37 °C. Optical density was measured at 600 nm and was 
used for evaluating the antimicrobial activity of tested compounds by comparing to untreated control. The MIC 
values were determined as the lowest dilutions of the compounds showing no turbidity.  
 
Reagents and analytics: All of the chemicals used were obtained from commercial sources (Acros, Aldrich, 
Alfa Aeser, Fluka), and were used without further purification. Solvents were used without purification or 
drying, unless otherwise stated. Reactions were monitored using analytical thin-layer chromatography plates 
(Merck, silica gel 60 F254, 0.25 mm), and the compounds were visualized with ultraviolet light and ninhydrin 
staining reagent. Silica gel grade 60 (particle size 0.040-0.063 mm; Merck, Germany) was used for flash-column 
chromatography. 1H and 13C NMR spectra were recorded on a Bruker AVANCE III 400 MHz spectrometer in 
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CDCl3 and DMSO-d6, solvents respectively, with TMS as the internal standard. Mass spectra were obtained 
with a VG-Analytical Autospec Q mass spectrometer (Centre for Mass Spectrometry, Institute Jožef Stefan, 
Ljubljana). Melting points were determined using a Reichert hot-stage microscope, and are uncorrected. HPLC 
analyses were performed on a Thermo Scientific Dionex UltiMate 3000 system (Thermo Fisher Scientific Inc., 
Waltham, MA, USA), using an Agilent Eclipse Plus C18 column (5 µm, 4.6 × 150 mm), at a flow rate of 1.5 
mL/min, temperature 25 °C and injection volume of 10 µL. The eluent was a mixture of 0.1% TFA in water (A) 
and acetonitrile (B). The gradient was 10% B to 90% B in 15 min, then 90% B for 5 min. The purity of the 
tested compounds was established to be ≥95%. 
 
Chemistry: Hit compound 13 (Table 2) was resynthesized along with four additional compounds (18, 24, 25 
and 30; Table 2). Key 5-(4-chlorophenyl)-1H-tetrazole intermediate 13a (Figure 7) was prepared by treatment of 
nitrile with sodium azide and ammonium chloride. N-Chloroacetamides were synthesized from different anilines 
and chloroacetyl chloride. All 2,5-disubstituted tetrazoles were obtained from N-chloroacetamides and tetrazole 
in ethanol in the presence of KOH. Finally, nitriles were converted to amides using alkaline hydrogen peroxide 
(Figure 7).[32] 
 
Figure 7: Synthesis of tetrazoles. Reagents and conditions: (a) NaN3, NH4Cl, DMF, 120 °C, 18 h; (b) 
chloroacetyl chloride, TEA,  DCM, 0°C - rt, 6 h; (c) KOH, EtOH, reflux, 16 h; (d) 30% H2O2, 1 M NaOH, 
DMSO, 0 °C - rt, 4 h. 
5-(4-Chlorophenyl)-1H-tetrazole (13a): To a solution of 4-chlorobenzonitrile (3.0 g, 21.8 mmol) in DMF (15 
mL), NaN3 (1.56 g, 24.0 mmol) and NH4Cl (1.28 g, 24 mmol) were added. The reaction mixture was stirred at 
120 °C for 16 h. The mixture was cooled to room temperature, and 1 M HCl (50 mL) was added. The formed 
white solid was filtered off, washed with water, and dried at 60 °C for 18 h. Yield = 94%; 1H NMR (400 MHz, 
DMSO-d6): δ 8.60 (d, 2H, J = 8.6 Hz, 2 × Ar-H), 8.08 (d, 2H, J = 8.6 Hz, 2 × Ar-H) ppm. 
 
General procedure for synthesis of compounds 24a, 25a and 30a: To a solution of different anilines (8.5 mmol) 
in DCM (25 mL), TEA (2.35 mL, 16.9 mmol) was added and the mixture was cooled to 0°C. Chloroacetyl 
chloride (0.750 mL, 9.35 mmol) diluted in DCM (10 mL) was added dropwise and the mixture was stirred for 6 
h at room temperature. To the reaction mixture, DCM (50 mL) was added and it was washed with water (50 
mL), 1 M HCl (2 × 50 mL), saturated aqueous NaHCO3 (50 mL) and brine (50 mL), dried with Na2SO4, and 
evaporated under reduced pressure. The solid was used without further purification.  
2-Chloro-N-(3-cyanophenyl)acetamide (24a):Yield = 61%; 1H NMR (400 MHz, CDCl3): δ 4.22 (s, 2H, CH2), 
7.46-7.50 (m, 2H, 2 × Ar-H), 7.73-7.76 (m, 1H, Ar-H), 8.00-8.01 (m, 1H, Ar-H), 8.34 (bs, 1H, NH) ppm.  
2-Chloro-N-(4-cyanophenyl)acetamide (25a): Yield = 66%; 1H NMR (400 MHz, DMSO-d6): δ 4.32 (s, 2H, 
CH2), 7.76-7.83 (m, 4H, 4 × Ar-H), 10.74 (bs, 1H, NH) ppm. 
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2-Chloro-N-phenylacetamide (30a): Yield = 73%; mp = 138-141°C (lit. 136-139 °C [32]); 1H NMR (400 MHz, 
DMSO-d6): δ 4.25 (s, 2H, CH2), 7.09 (t, 1H, J = 7.4 Hz, Ar-H), 7.33 (t, 1H, J = 7.9 Hz, Ar-H), 7.59 (d, 2H, J = 
7.8 Hz, 2 × Ar-H), 10.30 (bs, 1H, NH) ppm. 
General procedure for synthesis of compounds 24, 25 and 30: To a solution of KOH (3.75 mmol) in ethanol (20 
mL), 5-(4-chlorophenyl)-1H-tetrazole (2.5 mmol) and chloroacetamides (24a, 25a or 30a, 2.5 mmol) were 
added and the mixture was heated under reflux for 16 h. The reaction was cooled to room temperature and water 
(50 mL) was added. The formed precipitate was filtered off and recrystallized from ethanol to obtain pure final 
compounds. 
2-(5-(4-Chlorophenyl)-2H-tetrazol-2-yl)-N-(3-cyanophenyl)acetamide (24): Yield = 51%; white solid, mp = 
209-211°C; 1H NMR (400 MHz, DMSO-d6): δ 5.84 (s, 2H, CH2), 7.58-7.61 (m, 2H, 2 × Ar-H), 7.66 (d, 2H, J = 
8.6 Hz, 2 × Ar-H), 7.81-7.84 (m, 1H, Ar-H), 8.05-8.06 (m, 1H; Ar-H), 8.09-8.12 (d, 2H, J = 8.4 Hz, 2 × Ar-H), 
11.02 (bs, 1H, NH) ppm. 13C NMR (100 MHz, DMSO-d6): δ 55.36, 111.78, 118.48, 122.06, 123.97, 125.54, 
127.65, 128.13, 129.49, 130.50, 135.35, 138.90, 163.38, 163.62 ppm. ESI HRMS m/z calcd. for C16H11ClN6O 
[M-(H)]+ 337.0605, found 337.0604. HPLC: tR = 10.183 min (99% at 254 nm). 
2-(5-(4-Chlorophenyl)-2H-tetrazol-2-yl)-N-(4-cyanophenyl)acetamide (25): Yield = 46%; white solid, mp = 
228-230 °C; 1H NMR (400 MHz, DMSO-d6): δ 5.85 (s, 2H, CH2), 7.66 (d, 2H, J = 8.6 Hz, 2 × Ar-H), 7.77 (d, 
2H, J = 8.8 Hz, 2 × Ar-H), 7.83 (d, 2H, J = 8.8 Hz, 2 × Ar-H), 8.10 (d, 2H, J = 8.6 Hz, 2 × Ar-H), 11.10 (bs, 1H, 
NH) ppm. 13C NMR (100 MHz, DMSO-d6): δ 55.45, 105.87, 118.84, 119.43, 125.53, 128.13, 129.49, 133.49, 
135.35, 142.28, 163.38, 163.78 ppm. ESI HRMS m/z calcd. for C16H11ClN6O [M-(H)]+ 337.0605, found 
337.0609. HPLC: tR = 10.197 min (100% at 254 nm). 
2-(5-(4-Chlorophenyl)-2H-tetrazol-2-yl)-N-phenylacetamide (30): Yield = 58%; white needles,  mp = 210-
212°C; 1H NMR (400 MHz, DMSO-d6): δ 5.79 (s, 2H, CH2), 7.12 (t, 1H, J = 7.4 Hz, Ar-H), 7.35 (t, 2H, J = 7.9 
Hz, 2 × Ar-H), 7.60 (d, 2H, J = 8.3 Hz, 2 × Ar-H), 7.66 (d, 2H, J = 8.5 Hz, 2 × Ar-H), 8.11 (d, 2H, J = 8.5 Hz, 2 
× Ar-H), 10.66 (bs, 1H, NH) ppm. 13C NMR (100 MHz, DMSO-d6): δ 55.42, 119.30, 124.01, 125.60, 128.13, 
128.96, 129.48, 135.31, 138.15 162.83, 163.33 ppm. ESI HRMS m/z calcd. for C15H12ClN5O [M-(H)]+ 
312.0652, found 312.0655. HPLC: tR = 10.320 min (100% at 254 nm). 
General procedure for synthesis of compounds 13 and 18: To a cooled (0 °C) solution of nitrile (0.080 mg, 
0.236 mmol) in DMSO, 30% H2O2 (0.5 mL) and 1 M NaOH were added (0.70 mL, 0.700 mmol). The reaction 
mixture was stirred for 4 h at room temperature. It was quenched with saturated aqueous Na2SO3. The formed 
precipitate was washed with water and recrystallized from ethanol to obtain pure final compounds. 
3-(2-(5-(4-Chlorophenyl)-2H-tetrazol-2-yl)acetamido)benzamide (compound 13): Yield = 59%; white solid, mp 
= 244-246 °C; 1H NMR (400 MHz, DMSO-d6): δ 5.87 (s, 2H, CH2), 7.36 (bs, 1H, CONH2a), 7.40 (t, 1H, J = 7.8 
Hz, Ar-H), 7.59 (d, 1H, J = 8.8 Hz, Ar-H),  7.65 (d, 2H, J = 8.5 Hz, 2 × Ar-H), 7.82 (dd, 1H, J1 = 7.8, J2 = 1.9 
Hz, Ar-H), 8.03 (bs, 1H, CONH2b), 8.11 (d, 2H, J = 8.5 Hz, 2 × Ar-H), 8.19 (t, 1H, J = 1.9 Hz, Ar-H), 11.21(bs, 
1H, NH) ppm. 13C NMR (100 MHz, DMSO-d6): δ 55.48, 119.06, 121.99, 122.68, 125.61, 128.14, 128.68, 
129.47, 135.03, 135.28, 138.31, 163.09, 163.31, 167.58 ppm. ESI HRMS m/z calcd. for C16H13ClN6O2 [M-(H)]+ 
355.0737, found 355.0717. HPLC: tR = 7.883 min (100% at 254 nm). 
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 4-(2-(5-(4-Chlorophenyl)-2H-tetrazol-2-yl)acetamido)benzamide (compound 18): Yield = 66%; white solid, mp 
= 252-255 °C; 1H NMR (400 MHz, DMSO-d6): δ 5.94 (s, 2H, CH2), 7.28 (bs, 1H, CONH2a), 7.66 (d, 2H, J = 8.6 
Hz, 2 × Ar-H), 7.71 (d, 2H, J = 8.8 Hz, 2 × Ar-H), 7.86 (d, 2H, J = 8.8 Hz, 2 × Ar-H), 7.90 (bs, 1H, CONH2b), 
8.11 (d, 2H, J = 8.6 Hz, 2 × Ar-H), 11.31 (bs, 1H, NH) ppm. 13C NMR (100 MHz, DMSO-d6): δ 55.57, 118.56, 
125.60, 128.13, 128.45, 129.39, 129.46, 135.28, 140.89, 163.32, 163.37, 167.26 ppm. ESI HRMS m/z calcd. for 
C16H13ClN6O2 [M-(H)]+ 355.0710, found 355.0707. HPLC: tR = 7.860 min (100% at 254 nm). 
 
Identity and purity of screening hits: 
2-(5-(4-Chlorophenyl)-2H-tetrazol-2-yl)-N-(4-methyl-3-nitrophenyl)acetamide (26): 1H NMR (400 MHz, 
DMSO-d6): δ 2.38 (s, 3H, CH3), 5.85 (s, 2H, CH2), 7.57 (s, 2H, 2 × Ar-H), 7.67 (d, 2H, J = 8.6 Hz, 2 × Ar-H), 
7.83 (s, 1H, Ar-H), 8.10 (d, 2H, J = 8.6 Hz, 2 × Ar-H), 10.81 (bs, 1H, NH) ppm. ESI MS m/z calcd. for 
C16H13ClN6O3 [M-(H)]+ 372.07, found 370.92, [M+(Na)]+ 394.72. HPLC: HPLC: tR = 11.514 min (92% at 254 
nm). 
 
Results and Discussion 
Virtual Screening: Pharmacophore models are widely used as virtual screening filters and can be applied in 
ligand-based and structure-based design scenarios where compound databases are mapped to the pharmacophore 
model and key interactions are postulated for the hits of such VS studies.[33] With the help of recently available 
crystal structure information on MurB enzyme in complex with NADP+ (PDB IDs: 4JAY, 4JB1) and available 
enzymatic data on MurB in complex with the substrate UDP-GlcNAc-EP (PDB ID: 2MBR), the pharmacophore 
model was designed in a mixed ligand-based and structure-based manner. The pharmacophore model was used 
in a subsequent filtering step where previously curated ZINC-based LigandScout ldb conformer database was 
screened to identify an initial hit compound 13. The details are described in Methods and Materials chapter. 
 
Ligand-based drug design and biological evaluation: As the hit compound 13 showed promising inhibitory 
activity in low micromolar range (IC50 value of 34 µM), additional in silico analogue identification step was 
performed. From the compounds with highest similarity to 13, available compounds 19-23 and 26-29 were 
obtained as presented in Table 2. Furthermore, we have decided to resynthesize VS screening hit 13 and to 
synthesize additional compounds 18, 24, 25 and 30 in order to analytically validate the studied structures and 
perform an initial structure-activity relationship study on the tetrazole compound set (Table 2). All additional 13 
compounds were evaluated in vitro for their inhibition of E. coli MurB enzyme. The results are presented as 
residual activities (RAs) of MurB in the presence of 100 µM of each compound. For the compounds with RAs 
lower than 50%, the IC50 values were determined. It can be observed that para-chlorophenyl analogues display 
IC50 values from 25 to 90 µM with poorly tolerated chlorine atom replacements and relocations. The terminal 
para-carboxamide functional group is evidently not essential and can be replaced with nitrile or 4-methyl-3-
nitro derivatized phenyl ring. This observation is in accordance with Gilbert et al. where structurally similar 
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series of pyrazolidine-3,5-dione inhibitors of MurB roughly occupied the same pocket above the FAD N-5 atom 
with the para-chlorophenyl moiety. [17] 
 
The steady state analysis of enzyme kinetics was performed for the most potent compound 30. The best model 
revealed non-competitive binding of inhibitor with respect to NADPH, with Ki value of 63 ± 10 µM. The 
models of inhibition with respect to UDP-GlcNAc-EP showed no correlation. The positive control (compound 
5) was evaluated under the same conditions as our compounds and it inhibited MurB with an IC50 value of 20 ± 
2 µM (literature value 11.4 µM). [18] 
 
Molecular docking: Compounds 25, 18, 22, 30, 26 and 13 were the highest ranking and all shared similar 
predicted binding mode (Figure 8, c). The polar tetrazole core occupies the space of triphosphopyridine 
nucleotide sugar and phosphate, extending with the acetamido moiety towards the FAD N-5 atom, and Glu335 
and Ser239 residues. Terminal para-chlorophenyl ring attached to the position 5 of the tetrazole core is 
favorable for inhibitory activity as relocation or substitution of chlorine atom led to inactive compounds. Similar 
observation was interestingly also reported by Gilbert et al. in the study of structurally similar series of 
pyrazolidine-3,5-dione inhibitors of MurB.[17] For reference, pyrazolidine-3,5-dione compound 7f (Figure 8, c) 
reported by Kutterer et al., was also docked in our system where similar binding mode to tetrazole compounds 
was observed (Figure 8, c). Contrasting to para-chlorophenyl compounds, relocation of chlorine to ortho-
position on phenyl ring or substitution of chlorine atom with ortho-methyl substituent resulted in a slightly 
altered binding mode according to our molecular docking study. It can be postulated that π-π stacking of para-
chlorophenyl moiety between Tyr196 and Tyr264 residues is favorable with additional interactions between 
ligand tetrazol-acetamido central moiety towards Asn243 and Lys272 (Figure 8, b). Reported inhibitor 7f by 
Kutterer et al. branches the scaffold with additional para-chlorophenyl moiety that extends towards Asn243, but 
our reported tetrazoles can favorably reach deeper in the main pocket towards FAD, where a carboxamde or 
similar functional group can interact with FAD. Compounds could be therefore described as structural 
continuation of 1,2-bis(4-chlorophenyl) pyrazolidine-3,5-diones reported beforehand.[16] We also compared the 
docked poses of our tetrazole compounds and aligned them to the starting pharmacophore model. We observed a 
good correlation between common binding mode of tetrazole compounds and essential structural features 
imposed by the starting pharmacophore model used in VS scenario (Figure 8, d). 
 
Figure 8: a) Binding mode of compound 13 depicted in yellow; b) 2D projection of compound 13 in the active 
site with key interactions; c) Common binding mode observed for tetrazole compounds depicted yellow with 
superimposed docked pose of compound 7f reported by Kutterer et al. (depicted in magenta); d) Aligned docked 
poses for reported tetrazole compound series to the developed pharmacophore model used in the first step for 
VS campaign.  
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Conclusion 
In conclusion, a novel series of 5-substituted tetrazol-2-yl acetamido inhibitors of MurB have been identified 
through combined structure-based and ligand-based drug design methods. Several low micromolar inhibitors 
have been reported with compounds 13 (Figure 8, a), 26 and 30 displaying IC50 values of 34, 28 and 25 µM, 
respectively. If none of the tested compounds possessed in vitro antimicrobial activity against S. aureus and E. 
coli, the reported series nevertheless lends itself to further optimisation studies as similar scaffolds are reported 
in literature bearing antibacterial activity.[34] Furthermore, reported series is also of interest for biological 
evaluation of the compound effects on bacterial virulence. After a thorough analysis of the research field, this 
study is relevant in the context of antibacterial drug discovery, as there were few inhibitors reported up to date. 
Additional studies would enable further structure-activity relationship data, experimental insight into the binding 
modes and possible optimization towards antibacterial activity. 
 
Abbreviations 
FAD flavin adenine dinucleotide 
NADPH β-nicotinamide dinucleotide phosphate
MurNAc N-acetyl muramic acid 
PEP phosphoenolpyruvate 
UDP uridine 5’-diphosphate 
UDP-GlcNAc UDP-N-acetyl glucosamine 
UDP-GlcNAc-EP UDP-N-acetyl glucosamine-enolpyruvate
HBD H-bond donor pharmacophoric feature 
HBA H-bond acceptor pharmacophoric feature 
VS virtual screening 
 
Conflict of interest 
The authors declare they have no conflict of interest. 
 
Acknowledgments 
This study was supported by the Slovenian Research Agency (grants no. L1-6745, J1-6743 and Z1-8158). We 
thank Dr. Dušan Žigon (Mass Spectrometry Center, Jožef Stefan Institute, Ljubljana, Slovenia) for mass spectra. 
We also thank OpenEye Scientific Software (Santa Fe, New Mexico, USA) and Inte:Ligand (Software-
Entwicklungs und Consulting GmbH, Maria Enzersdorf, Austria) for their help and support. 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
References 
[1] E. D. Brown, G. D. Wright, Nature 2016, 529, 336. 
[2] K. Bush, Future Med. Chem. 2016, 8, 921. 
[3] K. Lewis, Nat. Rev. Drug Discov. 2013, 12, 371. 
[4] M. Hrast, I. Sosič, R. Šink, S. Gobec, Bioorg. Chem. 2014, 55, 2. 
[5] H. Gelband et al., CDDEP Report. The State of the World's Antibiotics, 2015, 
http://cddep.org/publications/state_worlds_antibiotics_2015 
[6] T. D. H. Bugg, D. Braddick, C. G. Dowson, D. I. Roper, Trends Biotechnol. 2011, 29, 167. 
[7] W. Vollmer, D. Blanot, M. A. De Pedro, FEMS Microbiol. Rev. 2008, 32, 149. 
[8] H. Barreteau, A. Kovač, A. Boniface, M. Sova, S. Gobec, D. Blanot, FEMS Microbiol. Rev. 2008, 32, 168. 
[9] T. Schneider, H-G. Sahl, Int. J. Med. Microbiol. 2010, 300, 161. 
[10] D. W. Green, Expert Opin. Ther. Targets 2002, 6, 1. 
[11] T. E. Benson, C. T. Walsh, J. M. Hogle, Structure 1996, 4, 47. 
[12] M. W. Chen, B. Lohkamp, R. Schnell, J. Lescar, G. Schneider, PLoS ONE, 2013, 8, 1. 
[13] C. J. Andres, J. J. Bronson, S. V. D'Andrea, M. S. Deshpande, P. J. Falk, K. A. Grant-Young, W. E. Harte, 
H-T. Ho, P. F. Misco, J. G. Robertson, D. Stock, Y. Sun, A. W. Walsh. Bioorg. Med. Chem. Lett. 2000, 
10, 715. 
[14] J. J. Bronson, K. L. DenBleyker, P. J. Falk, R. A. Mate, H-T. Ho, M. J. Pucci, L. B. Snyder. Bioorg. Med. 
Chem. Lett. 2003, 13, 873. 
[15] R. W. Sarver, J. M. Rogers, D. E. Epps, J. Biomol. Screen. 2002, 7, 21. 
[16] K. M. K. Kutterer, J. M. Davis, G. Singh. Y. Yang, W. Hu, A. Severin, B. A. Rasmussen, G. 
Krishnamurthy, A. Failli, A. H. Katz, Bioorg. Med. Chem. Lett. 2005, 15, 2527. 
[17] A. M. Gilbert, A. Failli, J. Shumsky, Y. Yang, A. Severin, G. Singh, A. H. Katz, J. Med. Chem. 2006, 49, 
6027. 
[18] G. D. Francisco, Z. Li, J. D. Albright, N. H. Eudy, A. H. Katz, P. J. Petersen, P. Labthavikul, G. Singh, Y. 
Yang, B. A. Rasmussen, Y. I. Lin, T. S. Mansour, Bioorg. Med. Chem. Lett. 2004, 14, 235. 
[19] J. J. Irwin, B. K. Shoichet, J. Chem. Inf. Model. 2005, 45, 177. 
[20] C. G. Wermuth, C. R. Ganellin, P. Lindberg, L. A. Mitscher, Pure Appl. Chem. 1998, 70, 1129. 
[21] G. Wolber, T. Langer, J. Chem. Inf. Model. 2005, 45, 160. 
[22] T. E. Benson, C. T. Walsh, J. M. Hogle, Biochemistry 1997, 36, 806. 
[23] G. Wolber, A. A. Dornhofer, T. Langer, J. Comput. Aided Mol. Des. 2006, 20, 773. 
[24] S. L. McGovern, B. T. Helfand, B. Feng, B. K. Shoichet, J. Med. Chem. 2003, 46, 4265. 
[25] J. B. Baell, G. A. Holloway, J. Med. Chem. 2010, 53, 2719. 
[26] W. P. Walters, M. Namchuk, Nat. Rev. Drug Discov. 2003, 2(4), 259. 
[27] P. C. D. Hawkins, A. G. Skillman, G. L. Warren, B. A. Ellingson, M. T. Stahl, J. Chem. Inf. Model. 2010, 
50, 572. 
[28] K. E., Hevener, W. Zhao, D. M. Ball, K. Babaoglu, J. Qi, S. W. White, R. E. Lee (2009). J. Chem. Inf. 
Model. 2009, 49(2), 444-460. 
[29] N. M. O'Boyle, M. Banck, C. A. James, C. Morley, T. Vandermeersch, G. R. Hutchison, J. Cheminform. 
2011, 3(1), 33. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
[30] T. E. Benson, J. L. Marquardt, A. C. Marquardt, F. A. Etzkorn, C. T. Walsh, Biochemistry 1993, 32, 2024. 
[31] European Committee for Antimicrobial Susceptibility Testing of the European Society of Clinical M, 
Infectious D. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth 
dilution. Clin. Microbiol. Infect. 2003, 9(8), IX. 
[32] A. K. Valiveti, U. M., Bhalerao, J. Acharya, H. N. Karade, R. Gundapu, A. K. Halve, M. P.  Kushik, 
Chem. Biol. Interact. 2015, 237, 125. 
[33] Q. Gao, L. Yang, Y. Zhu, Curr. Comput. Aided Drug Des. 2010, 6, 37. 
[34] B. Manjunatha, G. K. Nagaraja, K. Reshma, S. K. Peethamber, M. R. Shafeeulla, RSC Adv., 2016, 6, 
59375–59388. 
 
Figure Legends and Tables 
Figure 1: Catalytic consecutive and two-step mechanism of MurB. 
Figure 2: Previously described MurB inhibitors present in the scientific literature. 
Figure 3: Left: pharmacophore, created on the basis of NADP, chain A (PDB ID: 4JAY) with 
superposed shared pharmacophore with UDP-GlcNAc-EP (PDB ID: 2MBR). Middle: 
pharmacophore, created with superposed NADP. Right: pharmacophore, created with 
added exclusion sphere coat representing the available space in the active site (yellow – 
planar/aromatic with tolerance sphere of 1.5 Å, red – H-bond acceptor with vector and 
tolerance sphere of 1.5 Å, green – H-bond donor with vector and tolerance sphere of 1.5 Å, 
centered red sphere – ionisable feature with tolerance of 2.15 Å, grey – exclusion spheres 
with tolerance of 1 Å). 
Figure 4: Left: superposition of UDP-GlcNAc-EP (blue, PDB ID: 2MBR) and NADP (cyan with 
coloured atom types, PDB ID: 4JAY); FAD can be observed in almost identical binding 
mode. Right: calculated pharmacophore: hydrophobic 46.571907, -5.837457, 11.458156; 
ionisable 45.4222 -11.2288 11.2484; ionisable 45.8758 -13.7696 11.946; HBA 52.896 -
10.663 12.334, 50.177 -10.402 13.677; HBA 53.257 -9.782 15.791, 50.177 -10.402 13.677; 
HBA 47.614 -13.199 7.989, 47.208 -13.871 11.119; HBA 43.817, -13.738, 7.969, 45.229 -
11.925 9.78; HBA 47.614 -13.199 7.989, 45.229 -11.925 9.78; HBA 43.132 -3.175 13.229, 
45.933 -2.903 13.325; HBD 47.234 -3.916 14.773; 46.564 -1.598 16.459. 
Figure 5: Preparation of ZINC database for virtual screening.  
Figure 6: Lineweaver-Burk diagram of non-competitive binding mode of compound 30 versus 
NADPH. The concentration of NADPH (25, 50, 75, 100 and 200 µM) was varied at fixed 
concentration of UDP-GlcNAc-EP (50 µM). The concentrations of inhibitor were 0, 10, 20, 30, 50, 75 
and 100 µM. 
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Figure 7: Synthesis of tetrazoles. Reagents and conditions: (a) NaN3, NH4Cl, DMF, 120 °C, 18 h; (b) 
chloroacetyl chloride, TEA,  DCM, 0°C - rt, 6 h; (c) KOH, EtOH, reflux, 16 h; (d) 30% H2O2, 1 M 
NaOH, DMSO, 0°C - rt, 4 h. 
Figure 8: a) Binding mode of compound 13 depicted in yellow; b) 2D projection of compound 13 in 
the active site with key interactions; c) Common binding mode observed for tetrazole compounds 
depicted yellow with superimposed docked pose of compound 7f reported by Kutterer et al. (depicted 
in magenta); d) Aligned docked poses for reported tetrazole compound series to the developed 
pharmacophore model used in the first step for VS campaign. 
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Table 1: Top scoring and commercially available compounds after VS and biological evaluation. 
 
No Structure 
VS 
score
a
 
RA 
(%)b 
No Structure 
VS 
score
a
 
RA (%)b 
6 
 
95.37 100 12 
 
95.25 71 
7 
N N
NH
N
N S
O
N
H
F
 
95.34 / 13 
 
95.32 
22 
 IC50 = 
34 ± 4 
µM 
8 
 
95.31 100 14 
 
95.42 97 
9 
 
95.67 100 15 
 
95.34 71 
10 
 
75.41 100 16 
 
94.33 100 
11 
 
95.59 83 17 
 
94.70 78 
a Pharmacophore b Residual activity (in %) of the enzyme at 100 μM tested compound. 
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Table 2: Structural analogues of the hit compound 13 and their biological evaluation on MurB enzyme. 
 
No Structure RA (%)b or 
IC50 (µM)c 
No Structure RA (%)b or 
IC50 (µM)c 
13 
 
34 ± 3 µM 24 
 
51 ± 5 µM 
18 
 
90 ± 8 µM 25 
 
76% 
19 
 
75% 26 
 
28 ± 3 µM 
20 
 
84% 27 
 
79% 
21 
 
98% 28 
 
82% 
22 
 
71% 29 
 
70% 
23 
 
62% 30 
 
25 ± 2 µM 
 
b Residual activity (%) of the enzyme at 100 μM tested compound. c IC50 (µM) determined from 7 concentrations and curve fitted with 
logit-log plot.  
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